Martin C. Müller

Stefan W Krause, Alois Gratwohl, Claudia Haferlach, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.

Martin C. Müller, A. Skotnicki, A. Hochhaus, 2003, Leukemia research.

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

Martin C. Müller, I. Dufva, G. Martinelli, 2009, Blood.

Implications of BCR-ABL 1 kinase domain-mediated resistance in chronic myeloid leukemia

Martin C. Müller, J. Radich, M. Deininger, 2015 .

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.

Martin C. Müller, J. Radich, G. Martinelli, 2014, Leukemia research.

ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Martin C. Müller, P. Erben, R. Hehlmann, 2008, Haematologica.

High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Martin C. Müller, S. Molica, P. Vigneri, 2017, Clinical Cancer Research.

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

Martin C. Müller, H. Einsele, J. Hasford, 2014, Annals of Hematology.

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV

Martin C. Müller, J. Hasford, K. Spiekermann, 2013, Annals of Hematology.

Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale.

Helen E White, Dong-Wook Kim, Timothy Hughes, 2013, Clinical chemistry.

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Martin C. Müller, U. Olsson‐Strömberg, S. Mustjoki, 2014 .

Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38)

Martin C. Müller, R. Larson, B. Druker, 2010 .

Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment‐Free Remission in a EURO‐SKI Subtrial

Martin C. Müller, T. Brümmendorf, W. Hofmann, 2018, Clinical lymphoma, myeloma & leukemia.

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

Martin C. Müller, J. Lipton, R. Paquette, 2016 .

STOPPING TYROSINE KINASE INHIBITORS IN A VERY LARGE COHORT OF EUROPEAN CHRONIC MYELOID LEUKEMIA PATIENTS: RESULTS OF THE EURO-SKI TRIAL

Martin C. Müller, U. Olsson‐Strömberg, S. Mustjoki, 2016 .

Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial

Martin C. Müller, T. Brümmendorf, F. Mahon, 2015 .

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Martin C. Müller, E. Kimby, J. Delabie, 2008, Blood.

High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib

Martin C. Müller, C. Musolino, S. Forte, 2013 .

Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV

Martin C. Müller, H. Heimpel, J. Hasford, 2008 .

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

Martin C. Müller, M. Baccarani, H. Kantarjian, 2015, Journal of Cancer Research and Clinical Oncology.

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.

Martin C. Müller, M. Pirmohamed, S. Pushpakom, 2013, Blood.

Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.

Martin C. Müller, H. Heimpel, J. Hasford, 2009 .

Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib.

Martin C. Müller, M. Baccarani, J. Dipersio, 2013 .

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Martin C. Müller, R. Larson, M. Baccarani, 2016, Journal of the National Cancer Institute.

The ne plus ultra for deep BCR-ABL sequencing?

Martin C. Müller, 2013, Blood.

Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)

Martin C. Müller, M. Baccarani, J. Dipersio, 2013 .

Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.

Martin C. Müller, J. Radich, J. Lipton, 2008 .

Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV

Martin C. Müller, J. Hasford, S. Schnittger, 2008 .

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Martin C. Müller, L. Beppu, J. Radich, 2009 .

Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy

Martin C. Müller, B. Druker, C. Schoch, 2001 .

Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV,

Martin C. Müller, H. Einsele, K. Spiekermann, 2011 .

Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV

Martin C. Müller, H. Heimpel, H. Einsele, 2012 .

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Martin C. Müller, L. Beppu, J. Radich, 2009 .

New Drug for Chronic Myeloid Leukemia Might Stimulate the Market

Martin C. Müller, 2020, Clinical Cancer Research.

Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Martin C. Müller, M. Baccarani, H. Kantarjian, 2015 .

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.

Martin C. Müller, M. Baccarani, J. Dipersio, 2012 .

Weekend Drug Holiday of Dasatinib in CML Patients Not Tolerating Standard Dosing Regimens. Reducing Toxicity with Maintained Disease Control.

Martin C. Müller, P. Martiat, A. Hochhaus, 2009 .

Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy

Martin C. Müller, I. Glauche, I. Roeder, 2017, Haematologica.

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Martin C. Müller, J. Hasford, A. Zander, 2010, Blood.

Randomized Comparison of Primary Allogeneic Stem Cell Transplantation and Best Available Drug Treatment in Chronic Myeloid Leukemia.

Martin C. Müller, H. Heimpel, A. Gratwohl, 2006 .

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia : an analysis from the International Randomized Study of Interferon and STI 571 ( IRIS ) *

Martin C. Müller, J. Radich, R. Larson, 2010 .

Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study

Martin C. Müller, S. Mustjoki, K. Porkka, 2014 .

Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IV

Martin C. Müller, H. Heimpel, S. Schnittger, 2010 .

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Martin C. Müller, I. Dufva, G. Martinelli, 2010 .

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

Martin C. Müller, M. Baccarani, G. Rosti, 2011, Blood.

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

Martin C. Müller, I. Dufva, G. Martinelli, 2009, Blood.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013, Haematologica.

Molecular Response <1% BCR-ABL IS at 12 Months Is Associated with Improved Overall and Progression-Free Survival. the Randomized German CML-Study IV

Martin C. Müller, S. Schnittger, A. Gratwohl, 2010 .

Martin C. Müller, H. Kantarjian, R. Silver, 2010, Haematologica.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Martin C. Müller, N. Schmitz, J. Hasford, 2015, Blood.

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2012 .

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

Martin C. Müller, H. Einsele, J. Hasford, 2011, Blood.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Martin C. Müller, D. Colomer, J. Gabert, 2010, Blood.

Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV

Martin C. Müller, H. Einsele, M. Pfreundschuh, 2011 .

Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis

Martin C. Müller, C. Haferlach, A. Reiter, 2010, Haematologica.